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The impact of pretransplant (hematopoietic cell transplantation [HCT]) cytarabine consolidation therapy on
post-HCT outcomes has yet to be evaluated after reduced-intensity or nonmyeloablative conditioning. We
analyzed 604 adults with acute myeloid leukemia in ﬁrst complete remission (CR1) reported to the Center for
International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative
conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor
from 2000 to 2010. We compared transplant outcomes based on exposure to cytarabine postremissionedgments on page 207.
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E.D. Warlick et al. / Biol Blood Marrow Transplant 20 (2014) 202e208 203consolidation. Three-year survival rates were 36% (95% conﬁdence interval [CI], 29% to 43%) in the no
consolidation arm and 42% (95% CI, 37% to 47%) in the cytarabine consolidation arm (P ¼ .16). Disease-free
survival was 34% (95% CI, 27% to 41%) and 41% (95% CI, 35% to 46%; P ¼ .15), respectively. Three-year cu-
mulative incidences of relapse were 37% (95% CI, 30% to 44%) and 38% (95% CI, 33% to 43%), respectively
(P ¼ .80). Multivariate regression conﬁrmed no effect of consolidation on relapse, disease-free survival, and
survival. Before reduced-intensity or nonmyeloablative conditioning HCT, these data suggest pre-HCT
consolidation cytarabine does not signiﬁcantly alter outcomes and support prompt transition to transplant
as soon as morphologic CR1 is attained. If HCT is delayed while identifying a donor, our data suggest that
consolidation does not increase transplant treatment-related mortality and is reasonable if required.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION consecutive allogeneic and autologous HCT to a Statistical Center at the
Decision-making regarding type of consolidation therapy
after ﬁrst complete remission (CR1) for acute myeloid leu-
kemia (AML) depends on many patient- and disease-related
variables. Postremission consolidation cytarabine chemo-
therapy can potentially cure a subset of AML patients, espe-
cially those with core binding factor leukemias [1-3].
However, a meta-analysis has suggested a survival beneﬁt for
a broader application of allografts for all intermediate and
high risk AML patients in CR1, excluding only those with
good risk cytogenetic or molecular features [4].
When an allograft is planned in a patient with AML in
CR1, an abbreviated course of cytarabine consolidation
therapy is often offered before hematopoietic cell trans-
plantation (HCT) while a donor is being identiﬁed. Despite
this common practice, the impact of pretransplant consoli-
dation chemotherapy on post-HCT outcomes for AML CR1
patients has not been prospectively evaluated. This question
has been retrospectively addressed by prior Center for In-
ternational Blood andMarrow Transplant Research (CIBMTR)
and European Group for Blood and Marrow Transplantation
analyses with myeloablative (MA) conditioning. Pretrans-
plant consolidation therapy did not alter survival or relapse
and did not increase transplant-related mortality (TRM)
[5,6]. The inﬂuence of pretransplant cytarabine consolidation
chemotherapy in the setting of reduced-intensity condi-
tioning (RIC)/non-MA (NMA) HCT for this patient population
is uncertain. Prior retrospective analyses comparing out-
comes after MA or RIC/NMA conditioning suggest a higher
rate of relapse after RIC/NMA HCT but less TRM and thus
similar survivals, even in older populations receiving RIC HCT
[7-9]. These data would theoretically lead to the hypothesis
that pre-HCT chemotherapy might reduce relapse risk after
RIC all-HCT. Most recent retrospective and prospective
publications, however, have challenged this earlier supposi-
tion, showing relatively similar relapse and TRM, regardless
of conditioning intensity [10-13].
In the context of expanding use of RIC/NMA HCT, a setting
where more stringent disease control may be desirable, the
effectiveness of pre-HCT consolidation chemotherapy is
largely unknown. A retrospective analysis from the Univer-
sity of Minnesota compared the outcomes of 60 AML patients
in CR1 undergoing the same RIC HCT from 2001 to 2008
based on exposure to pre-HCT consolidation chemotherapy
[14]. The investigators reported similar relapse and survival
in subjects who did or did not receive pre-HCT consolidation
[14]. To deﬁne the value of pre-RIC/NMA HCT consolidation
chemotherapy for AML in CR1, we addressed this question in
a large dataset from the CIBMTR.METHODS
Data Source
The CIBMTR includes a voluntary working group of more than
450 transplantation centers worldwide that contribute detailed data onMedical College of Wisconsin in Milwaukee and the National MarrowDonor
Program Coordinating Center in Minneapolis. Participating centers are
required to report all transplants consecutively; patients are followed
longitudinally, and compliance is monitored by on-site audits. Computer-
ized checks for discrepancies, physicians’ review of submitted data, and on-
site audits of participating centers ensure data quality. Observational studies
conducted by the CIBMTR are performed in compliance with all applicable
federal regulations pertaining to the protection of human research partici-
pants. Protected Health Information used in the performance of such
research is collected and maintained in CIBMTR’s capacity as a Public Health
Authority under the HIPAA Privacy Rule.Patient Selection
All adult patients reported to the CIBMTR who received a RIC or NMA
conditioning HCT for AML in CR1 from either an HLA-identical sibling, un-
related donor (URD), or umbilical cord blood (UCB) donor from 2000 to 2010
were included in this analysis. Patients with French American British (FAB)
subtype M3 were excluded. The very few patients with favorable risk cy-
togenetics (n ¼ 8) were also excluded.
A total of 604 patients was identiﬁed from 165 centers. Patients were
initially divided into 3 cohorts for analysis: (1) no postremission therapy
before transplant, (2) standard-dose cytarabine consolidation therapy
(deﬁned as1 g/m2/day on earlier CIBMTR data submission forms [pre-2008]
or 2 g/m2/day on current forms), or (3) high-dose cytarabine consolidation
therapy (deﬁned as >1 g/m2/day on earlier forms or >2 g/m2/day on current
forms). However, because no difference was seen between lower and higher
dose consolidation cohorts, the ﬁnal analysis compared no cytarabine
consolidation versus any dose of cytarabine consolidation.
Patients included in the study cohort received a maximum of 2 cycles of
induction therapy to obtain CR1 status. CIBMTR classiﬁcations of URD
matching were used to deﬁne well-matched, partially matched, or mis-
matched categories [15]. Preparative regimens were classiﬁed as either RIC or
NMA by established CIBMTR functional deﬁnitions. RIC included any regimen
with either (1) 500 cGy or less of total body irradiation as a single fraction or
800 cGy or less if fractionated (2) <9 mg/kg busulfan oral (or intravenous
equivalent), (3) <140 mg/m2 melphalan, (4) <10 mg/kg thiotepa, or (5)
BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [16,17].
All other regimens were classiﬁed as NMA conditioning according to
Champlin et al. [18] where prompt hematopoietic recovery could reasonably
be expected without a transplant and would produce mixed chimerism
after engraftment post-transplant. Based on these classiﬁcations, the most
common RIC regimens included (1) ﬂudarabineþ busulfan, (2) ﬂudarabineþ
melphalan, (3) ﬂudarabine þ cyclophosphamide, and (4) other. NMA regi-
mens included ﬂudarabineþ low-dose total body irradiation (200 cGy) and
ﬂudarabine þ antithymocyte globulin.Study Endpoints
The primary endpoint was overall survival (OS) in those with or
without pre-HCT consolidation chemotherapy. Secondary endpoints
included hematopoietic recovery, occurrence of acute and chronic graft-
versus-host disease (GVHD), TRM, incidence of relapse, and disease-free
survival (DFS). OS was deﬁned as time to death from any cause with sur-
viving patients censored at time of last contact. Hematopoietic recovery
was deﬁned as time to absolute neutrophil count  500 neutrophils/mL
sustained for 3 consecutive days. Criteria for acute and chronic GVHD were
based on consensus criteria as previously deﬁned [19,20]. TRMwas deﬁned
as any death in the ﬁrst 28 days post-transplant or any death after day 28
without recurrent leukemia. Relapse was deﬁned as hematologic evidence
of disease recurrence with those surviving without relapse censored at the
date of last contact and using death in remission as the competing hazard.
DFS was deﬁned as survival without death or relapse with those who
survived without recurrence or persistent disease censored at the date of
last contact.
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Patient, disease, treatment history, and transplant-related factors
were compared between groups using the chi-square test for categorical
variables and the Wilcoxon two-sample test for continuous variables. The
product-limit estimator proposed by Kaplan and Meier [21] was used to
estimate the median and range of follow-up time.
Univariate probabilities of DFS and OSwere calculated using the Kaplan-
Meier estimator with the variance estimated by Greenwood’s formula [21].
Probabilities of acute and chronic GVHD, TRM, and relapse were calculated
using cumulative incidence curves to accommodate competing risks.
Ninety-ﬁve percent conﬁdence intervals (CIs) for all probabilities and P
values of pairwise comparisons were derived from pointwise estimates and
calculated using an arcsine square root transformation.
The ﬁnal consolidation therapy groups used for analysis were no
consolidation versus any dose cytarabine consolidation after initial analyses
showing no cytarabine dose effect. The proportional hazards assumption for
all variables was examined and its violations addressed by using a stratiﬁed
Cox model when needed. A backward elimination method was used to build
the regressionmodel for the outcomes of TRM, relapse, DFS, and OS. Because
exposure to cytarabine-based consolidation was the main interest of the
study, the risk factor of cytarabine consolidation was included in all steps of
model building. Patient-related variables, including age (<45, 45 to 60,
>60), gender, and Karnofsky Performance Status (<90% versus 90%),
were considered in the analysis. Disease-related variables included FAB
or World Health Organization subtype (FAB M0/M1/M2 versus M4/M5/M6/
M7 versus AML Not Otherwise Speciﬁed versus all remaining categories
versus missing), antecedent hematologic disorder (yes or no), cytogenetics
at diagnosis by Southwest Oncology Group criteria [2] (intermediate
versus unfavorable versus unknown signiﬁcance), and number of cycles
of induction chemotherapy (1 versus 2). Transplant-related variables
included year of transplant (2000 to 2005 versus 2006 to 2008 versus 2008
to 2010), donor source (matched sibling versus matched URD versus UCB
versus other URD), recipient cytomegalovirus serostatus (negative versus
positive versus missing), conditioning regimen (ﬂudarabine þ busulfan
versus ﬂudarabine þ melphalan versus ﬂudarabine þ cyclophosphamide
and “other” versus NMA), GVHD prophylaxis (tacrolimus based versus
cyclosporine based), and antithymocyte globulin or alemtuzumab exposure
(yes or no).
Risk factors with a signiﬁcance level of P < .05 were included in the
model. The potential interaction between main effect of pretransplant
consolidation therapy exposure and all signiﬁcant covariates were exam-
ined. Adjusted probability of DFS and OS were computed based on the ﬁnal
Cox regression model, stratiﬁed by age, and weighted by the pooled sample
proportion value for all signiﬁcant risk factors. SAS software (SAS Institute,
Cary, NC) was used to perform all statistical analyses.
RESULTS
Patient disease, treatment, and transplant-related factors
are shown in Table 1. All patients received induction chemo-
therapy with either 3 þ 7 based (anthracycline þ cytarabine)
(85%) or other multidrug induction regimens including
mitoxantrone and etoposide (4%), cytarabine regimens
without anthracycline (9%), and others (2%) (clofarabine,
gemtuzumab, topotecan, amsacrine, enocitabine, or anthra-
cycline alone). Median age, performance status, presence
of extramedullary disease, median WBC count at diagnosis,
graft source, type of GVHD prophylaxis, and use of antithy-
mocyte globulin or alemtuzumab were similar between the
2 groups.
Between the consolidation groups, those receiving no
consolidation had a slightly higher percentage of AML Not
Otherwise Speciﬁed (25% compared with 18%), had a
slightly higher percentage of “other” multiagent induction
chemotherapy (22% versus 11%), were more likely to have
previously undergone 2 cycles of induction before CR1
documentation (33% versus 19%), and were more likely to
have an antecedent hematologic disorder (myelodysplastic
syndrome/myeloproliferative neoplasm) (34% versus 19%).
Those receiving no consolidation also had a slightly higher
percentage of ﬂudarabine þ melphalan conditioning (25%
versus 13%) compared with the cytarabine consolidation
group. Those receiving no cytarabine consolidation were
slightly less likely to be classiﬁed as an FAB subtype ofM4/M5/M6//M7 (20% versus 32%) and have intermediate
risk cytogenetics (38% versus 48%). The median follow-up
between the groups was similar (36 months for no
consolidation versus 35 months for those receiving
consolidation).
Outcomes
After a median follow-up of 36 months (range, 3 to 132),
239 patients were alive at last contact. Two hundred
seventeen patients had relapsed and died, and 20 patients
had relapsed but were alive at last contact.
Three-year OS was similar between the groups: 36% (95%
CI, 29% to 43%) for those receiving no consolidation
compared with 42% (95% CI, 37% to 47%) in the consolidation
group (P ¼ .15) (Figure 1). There was no signiﬁcant difference
in the incidence of relapse. The no consolidation group had a
3-year cumulative incidence of relapse of 37% (95% CI, 33% to
43%) versus the consolidation group at 38% (95% CI, 33% to
43%; P ¼ .80) (Figure 2).
Neutrophil engraftment at Day þ28 was similar between
groups, with no consolidation at 86% (95% CI, 77% to 92%) and
consolidation at 82% (95% CI, 75% to 87%). The cumulative
incidence of grades III to IV acute GVHD was similar at 16%
(95% CI, 12% to 22%) and 13% (95% CI, 10% to 16%), respectively
(P ¼ .26). The incidence of chronic GVHD at 3 years was
identical between the 2 groups at 41% (P ¼ .96).
TRM at Day þ100 was slightly higher in the no consoli-
dation group at 12% (95% CI, 8% to 17%) compared with 5%
(95% CI, 4% to 8%) in the consolidation group (P ¼ .01). This
difference was maintained at 1 year with a TRM of 23% (95%
CI, 17% to 29%) in the no consolidation group versus 16% (95%
CI, 12% to 20%) in the consolidation group (P ¼ .04).
Three-year DFS for the no consolidation group was 34%
(95% CI, 27% to 41%) compared with 41% (95% CI, 35% to 46%)
for the group receiving consolidation (P ¼ .15) (Table 2).
Additional supplemental univariate analyses investigating
the impact of cytogenetic risk group, type of induction
chemotherapy, conditioning regimen, and donor source on
post-HCT outcomes revealed no unique factors of signiﬁ-
cance (data not shown). These analyses found that unfavor-
able cytogenetics, UCB donor source, and ﬂudarabine plus
melphalan conditioning were the only factors of signiﬁcance
inﬂuencing relapse or TRM, mirroring the ﬁndings of our
primary analysis focusing on cytarabine consolidation
exposure.
A forward stepwise method was used to build the
regression models and compare risks for TRM, relapse, DFS,
and OS in multivariate analyses, adjusting for the effects of
other signiﬁcant covariates (Table 3). Similar outcomes
regardless of consolidation exposure were conﬁrmed for OS,
DFS, and relapse. The modest univariate difference in TRM
between the 2 groups was not conﬁrmed in multivariate
analysis. Unfavorable cytogenetics was the only signiﬁcant
factor inﬂuencing relapse. TRM was worse with UCB donor
source, ﬂudarabine þ melphalan conditioning, and age > 60
but was better in women. OS was worse with UCB donor
source, unfavorable cytogenetics, age > 60, and male gender.
DISCUSSION
In persons with AML in CR1 receiving a RIC/NMA alloge-
neic HCT, we found no difference in outcomes between those
who did or did not receive pre-HCT cytarabine consolidation.
Our data highlight similar OS, DFS, and relapse post-RIC/
NMA HCT with no increased TRM after cytarabine consoli-
dation. The precise evaluation of potential beneﬁt or harm of
Table 1
Characteristics of Adult Patients (18 Years) Receiving RIC/NMA HCT for
AML in CR1 between 2000 and 2010
Characteristics No Cytarabine
Consolidation
Cytarabine
Consolidation
P
No. of patients 202 402
No. of centers 90 75
Patient-related characteristics
Age at transplant, yr, median
(range)
60 (18-75) 59 (19-76) .18
Age .29
Less than 45 years 21 (10%) 41 (10%)
45-60 76 (38%) 177 (44%)
Greater than 60 105 (52%) 184 (46%)
Gender .16
Male 125 (52%) 225 (55%)
Female 77 (38%) 177 (45%)
Karnofsky Performance Status .84
90%-100% 133 (66%) 268 (67%)
Less than 90% 60 (30%) 120 (30%)
Missing 9 (4%) 14 (3%)
Disease-related characteristics
FAB subtype <.01
M0,M1/M2 64 (32%) 139 (35%)
M4/M5/M6/M7 40 (20%) 127 (32%)
AML NOS 51 (25%) 74 (18%)
Miscellaneous 21 (10%) 31 (7.5%)
Other/missing 26 (13%) 31 (7.5%)
WBC count at diagnosis .16
 to 5  107/L 110 (54%) 195 (49%)
<5  107/L 92 (46%) 207 (51%)
Extramedullary disease at
diagnosis
.67
Absent 193 (96%) 382 (95%)
Present 8 (4%) 44 (5%)
Cytogenetics (SWOG
classiﬁcation)
.03
Intermediate 77 (38%) 193 (48%)
Unfavorable 63 (31%) 119 (30%)
Unknown signiﬁcance 62 (31%) 90 (22%)
Pre-existing MDS/MPN <.01
No 134 (66%) 327 (81%)
Yes 68 (34%) 75 (19%)
Time from diagnosis to CR1, mo,
median (range)
1.6 (<1-89) 1.3 (<1-160) <.0001
0-2 120 (59%) 306 (76%)
2-6 60 (30%) 88 (22%)
6þ 22 (11%) 8 (2%)
Treatment characteristics
Induction regimen <.01
3 þ 7 or “similar” 157 (78%) 358 (89%)
Other multiagent induction 45 (22%) 44 (11%)
Cycles of induction
chemotherapy
<.01
1 136 (67%) 326 (81%)
2 66 (33%) 76 (19%)
Cycles of cytarabine
consolidation
1 N/A 168 (42%)
2 or more N/A 134 (33%)
Unknown number N/A 100 (25%)
Year of transplant <.01
2000-2005 53 (26%) 106 (26%)
2006-2008 84 (42%) 148 (37%)
2008-2010 65 (32%) 148 (37%)
Graft source .51
Matched sibling donor 106 (52%) 185 (46%)
Matched URD 52 (26%) 117 (29%)
Partially matched URD 16 (8%) 38 (9%)
UCB 28 (14%) 62 (15%)
Recipient CMV serostatus .29
Negative 61 (30%) 128 (32%)
Positive 141 (70%) 269 (67%)
Missing 0 (0%) 5 (1%)
Conditioning regimens
RIC .045
Flu/Bu 89 (44%) 173 (43%)
(continued)
Table 1
(Continued)
Characteristics No Cytarabine
Consolidation
Cytarabine
Consolidation
P
Flu/Mel 51 (25%) 54 (13%)
Flu/Cy þ other 36 (18%) 97 (24%)
NMA
Flu/TBI (200-500 cGy) 23 (11%) 71 (18%)
Flu/ATG 3 (2%) 7 (2%)
GVHD prophylaxis .32
Tacrolimus based 115 (57%) 212 (53%)
Cyclosporine based 87 (43%) 190 (47%)
ATG/alemtuzumab use .06
No 133 (66%) 235 (58%)
Yes 69 (34%) 167 (42%)
Time from CR1 to transplant,
mo, median (interquartile
range, 25%-75%)
2 (1-4) 4 (3-5) <.0001
Follow-up of survivors, mo,
median (range)
36 (3.9-115) 35 (3.2-132) .25
NOS indicates Not Otherwise Speciﬁed; SWOG, Southwest Oncology Group;
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; CMV,
cytomegalovirus; Flu, ﬂudarabine; Bu, busulfan; Mel, melphalan; Cy,
cyclophosphamide; TBI, total body irradiation; ATG, antithymocyte glob-
ulin.
Miscellaneous AML subtypes included AML with abnormal
eosinophilsþAMLwith 11q23þAMLwithmultilineage dysplasia; induction
chemotherapy: 3 þ 7 ¼ anthracycline (idarubicin or
daunorubicin) þ cytarabine; other multiagent induction (n ¼ 89) included
mitoxantrone þ etoposide (4%), cytarabine without anthracycline (9%), and
others (2%) (clofarabine, gemtuzumab, topotecan, amsacrine, enocitabine,
anthracycline alone).
E.D. Warlick et al. / Biol Blood Marrow Transplant 20 (2014) 202e208 205giving cytarabine consolidation requires a randomized trial;
however, no such study is reported or likely to be completed.
These results are similar to the ﬁndings previously reported
by others in the MA setting [5,6].
Because the use of RIC regimens for HCT continues to
expand, efforts to optimize both efﬁcacy and safety of ther-
apy continue. Several retrospective studies comparing MA
conditioning with RIC have suggested an increased risk of
relapse with RIC accompanied in some series by improved
TRM [7-9], suggesting that RIC conditioning is potentially
less effective in control of residual leukemia during CR.
However, more recent studies [11-13] have revealed similar
relapse, TRM, and OS regardless of conditioning intensity for
AML patients transplanted in CR. The ﬁnding that post-HCT
outcomes are not improved by cytarabine consolidation
chemotherapy before RIC/NMA HCT supports the contention
that RIC can effectively control disease recurrence in CR1Figure 1. Comparison of survival post-transplant between AML CR1 subjects
who did or did not receive pretransplant cytarabine consolidation.
Figure 2. Comparison of post-transplant relapse incidence between AML CR1
subjects who did or did not receive pretransplant cytarabine consolidation.
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theories.
Only limited data have been available to help guide
consolidation chemotherapy decision-making before a RIC/
NMA HCT. McCormack et al. [14] described the University of
Minnesota experience with similar survival and relapse rates
regardless of cytarabine consolidation using a uniform RIC
regimen for AML. The current larger study, with diverse
conditioning regimens, reveals similar ﬁndings and has
substantially more power to identify any potentially differing
outcomes regardless of cytarabine consolidation exposur-
edand none was found.
Pretransplant cytarabine consolidation did not increase
the risk of TRM. Physicians may, however, choose patients
with a better performance status to receive consolidation
chemotherapy before HCT and proceed directly to HCT for
those patients who tolerated induction chemotherapy poorly
or alternatively choose consolidation in those with higher
relapse risks. We do not have data to directly examine the
treating physician rationale for giving consolidation
chemotherapy before RIC HCT. Our multivariate analysis did
not demonstrate any difference in TRM based on consolida-
tion exposure but did show higher TRM after UCB HCT inTable 2
Outcomes after RIC/NMA HCT Based on Cytarabine Consolidation Exposure: Univa
No Cytarabine Consolidation
No. Assessable Incidence (95% C
OS
At 2 yr 202 42 (35-49)
At 3 yr 202 36 (29-43)
Relapse
At 2 yr 197 33 (27-40)
At 3 yr 197 37 (30-44)
Acute GVHD grades III-IV 202
At Day þ100 16 (12-22)
Chronic GVHD 195
At 3 yr 41 (34-49)
TRM
At 100 d 197 12 (8-17)
At 1 yr 197 23 (17-29)
DFS
At 2 yr 197 39 (32-46)
At 3 yr 197 34 (27-41)men, in those receiving ﬂudarabine plus melphalanebased
conditioning, and in those older than 60.
Our analysis was designed to investigate cytarabine
consolidation but also any potential cytarabine dose effect. In
the past, the advantage of high dose cytarabine consolidation
without HCT was noted primarily for persons with good risk
cytogenetics [1] or younger patients (<60 years) with normal
cytogenetics [22]. Thus, it is not surprising that we found
similar outcomes regardless of cytarabine dose in this data-
set that excluded patients with good risk cytogenetics and
included a large subset of patients over the age of 60
[1,22,23]. These data support the theory that in AML patients
in CR1, the graft-versus-leukemia effect provided by the
allograft can eliminate residual disease in long-term survi-
vors, even after RIC/NMA HCT. We analyzed only patients in
morphologic CR as reported by the participating centers.
Emerging literature suggest that minimal residual disease
deﬁned by either cytogenetic, molecular, or multiparameter
ﬂow cytometry, may inﬂuence post-HCT outcomes and may
identify patients with higher risk of relapse [24,25]. Future
analysis should consider depth of remission deﬁned by cy-
togenetic, molecular, and ﬂow cytometric data to investigate
the value of added pre-HCTcytarabine or other consolidation
to reduce tumor burden before RIC allogeneic HCT, but these
data suggest lesser importance of this minimal disease
burden during CR1.
We acknowledge the inherent limitations of an analysis
using an observational database. We cannot account for
those who relapsed before HCT and were excluded, yet the
median time to HCT we studied was only 2 and 4 months
for the 2 cohorts, capturing most of the higher risk period.
In addition, some differences between the 2 groups merit
discussion. Those requiring 2 rounds of induction before
CR1 more often had no consolidation. However, it is un-
certain if 2 rounds of induction chemotherapy were given
after the absence of a remission after the ﬁrst induction
cycle. More patients in the no consolidation group had
preceding myelodysplastic syndrome/myeloproliferative
neoplasm, another factor that might favor the consolida-
tion arm. Finally, in this dataset we did not have the
important data regarding FLT-3 ITD (FMS-like tyrosine ki-
nase-3 Internal Tandem Duplication) and NPM1 (nucleo-
phosmin 1) mutational status. Given this limitation,
application of these data to those with known molecularriate Analysis
Cytarabine Consolidation P
I) No. Assessable. Incidence (95% CI)
402 47 (42-52) .25
402 42 (37-47) .16
393 37 (32-41) .42
393 38 (33-43) .80
402
13 (10-16) .26
395
41 (36-47) .96
393 5 (4-8) .01
393 16 (12-20) .04
393 44 (39-49) .20
393 41 (35-46) .15
Table 3
Outcome after RIC/NMA HCT: Multivariate Analysis
Outcome Variable Relative Risk 95% CI P
OS Consolidation
No 1
Yes .886 .71-1.10 .28
Donor source
Matched sibling 1
Matched URD .88 .68-1.14 .34
Partially matched URD 1.03 .71-1.51 .86
UCB 1.60 1.18-2.16 .002
Cytogenetics
Intermediate 1
Unfavorable 1.74 1.36-2.22 <.0001
Other/missing 1.20 .92-1.56 .18
Age
<45 1
45-60 1.22 .83-1.79 .31
>60 1.51 1.03-2.2 .03
Gender
Male 1
Female .78 .63-.97 .02
TRM Consolidation
No 1
Yes .74 .53-1.04 .08
Donor source
Matched sibling 1
Matched URD .998 .65-1.52 .99
Partially matched URD 1.371 .79-2.39 .26
UCB 3.83 2.25-6.54 <.0001
Conditioning
Flu/Bu 1
Flu/Mel 1.6 1.05-2.43 .03
Flu/other .65 .38-1.14 .13
TBI based .94 .56-1.6 .80
Age
<45 1
45-60 1.2 .63-2.28 .58
>60 1.96 1.04-3.67 .04
Gender
Male 1
Female .65 .46-.91 .013
Relapse Consolidation
No 1
Yes 1.03 .77-1.36 .86
Cytogenetics
Intermediate 1
Unfavorable 1.87 1.38-2.5 <.0001
Other/missing 1.17 .83-1.66 .37
WBC count
<5.0 1
5.0 .77 .59-.99 .05
DFS Consolidation
No 1
Yes .87 .7-1.07 .19
Cytogenetics
Intermediate 1
Unfavorable 1.65 1.29-2.1 <.0001
Other/missing 1.19 .92-1.55 .19
Gender
Male 1
Female .75 .60-.92 .0071
Donor source
Matched sibling donor 1
Matched URD .84 .64-1.09 .20
Partially matched URD .94 .64-1.36 .72
UCB 1.37 1.01-1.85 .04
Relapse and DFS models were stratiﬁed on ATG/alemtuzumab use.
E.D. Warlick et al. / Biol Blood Marrow Transplant 20 (2014) 202e208 207signatures implying increased relapse risk, such as FLT-3
ITD, would not be recommended. In the absence of those
molecular signatures, however, the results clearly show no
difference in outcome based on pre-HCT consolidation
exposure and support a recommendation to proceed
promptly to transplant as soon as CR1 is attained. If HCT isdelayed by the time required to identify a suitable donor,
our data suggest that consolidation does not increase HCT
TRM and its use is acceptable in that setting.
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